子宫颈癌患者新辅助化疗前后癌组织中mdrl、肺耐药蛋白mRNA及其蛋白的表达变化和意义

摘要

目的 寻找预测子宫颈癌新辅助化疗效果的分子生物学指标.方法 采用real time RTPCR和免疫组织化学法检测40例子宫颈癌患者新辅助化疗前后癌组织中mdrl、肺耐药蛋白(LRP)mRNA及其编码蛋白P-gP、LRP表达水平.结果 新辅助化疗前后子宫颈癌组织中mdrl的表达量分别为(45.800 ±0.636、62.381±0.743,t=-66.582,P＜0.01);新辅助化疗前后子宫颈癌组织中LRP mRNA的表达量分别为(50.048±0.770、66.912±0.752,t=-78.604,P＜0.01);新辅助化疗前后子宫颈癌组织中P-gP的阳性表达分别为40.0%(16/40)、70.0%(28/40),χ2=7.273,P=0.007;新辅助化疗前后子宫颈癌组织中LRP的阳性表达分别为62.5%(25/40)、92.5%(37/40),χ2=10.323,P=0.001,新辅助化疗后mdrl、LRPmRNA及其编码蛋白P-gP、LRP表达水平较化疗前明显升高,2组比较差异有统计学意义(P＜0.01).P-gP、LRP表达与患者年龄、肿瘤大小、临床分期、病理分级无关(P＞0.05);P-gP蛋白的阳性与阴性患者其化疗有效率分别为6(37.5%)、17(70.8%),2组比较差异有统计学意义(χ2=4.365,P＜0.05).LRP蛋白的阳性与阴性患者其化疗有效率分别为12(48.O%)、13(86.7%),2组比较差异有统计学意义(χ2=5.980,P＜0.05);P-gP与LRP成正相关(χ2=4.177,r=0.323,P＜0.05).结论 P-gP、LRP表达状态有可能作为预测化疗效果的参考指标.%Objective To explore the biological parameter predicting the effect of neoadjuvant chemotherapy in cervical carcinoma.Methods The expressions of the P-glucoprotein(P-gp)and lung resistance protein(LRP)as well mdrl and LRP mRNA were examined by real time RT-PCR and immunohistochemical assay in 40 specimens of cervical carcinoma before and after neoadjuvant chemotherapy.Results The expression level of mdrl was[(45.800±0.636)vs(62.381±0.743),t=-66.582,P＜0.01],the expression level of LRP mRNA was [50.048±0.770、66.912±0.752,t=-78.604,P＜0.01]before and after neoadjuvant chemotherapy The positive expression of P-gp was[40.0%(16/40)、70.0%(28/40),χ2=7.273,P=0.007]and that of LRP was [62.5%(25/40)、92.5%(37/40),χ2=10.323,P:0.001],which were significantly higher than that before neoadjuvant chemotherapy(P＜0.01);the expressions of P-gp and LRP were irrelated to age,tumor size,TNM stage and pathology grade(P＞0.05);the effective rate of chemotherapy was 6(37.5%)in P-gP positive patients and 17 (70.8%)in P-gp negative patients(χ2=4.365,P＜0.05),while the effective rate of chemotherapy was 12 (48.0%)in LRP positive patients and 13(86.7%)in LRP negative patients(χ2=5.980,P＜0.05).The expression of P-gp was positively correlated with the expressions of LRP(χ2=4.177,r=0.323,P＜0.05).Conclusion The P-gp and LRP expression status can be used as a biological parameter to predict the effect of neoadjuvant chemotherapy.